SCHEMBL17784159

SCHEMBL17784159

CCCC(=O)OC[C@H]1O[C@@H](OC(C)=O)[C@@H](NC(C)=O)[C@@H](OC(C)=O)[C@@H]1OC(C)=O

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 3/20 0.59
KMT2A Q03164 1/20 0.59
POLB P06746 2/20 0.53
ALDH1A1 P00352 2/20 0.53
CYP3A4 P08684 1/20 0.49
MAPT P10636 1/20 0.49
CYP2C9 P11712 1/20 0.49
CYP2C19 P33261 1/20 0.49
KDM4E B2RXH2 1/20 0.48
TGM2 P21980 1/20 0.47
CYP2D6 P10635 1/20 0.43
THRB P10828 1/20 0.43
HSD17B10 Q99714 1/20 0.43
CA2 P00918 6/20 0.42
CA1 P00915 5/20 0.42
CA9 Q16790 5/20 0.42
CA12 O43570 4/20 0.42
NR3C1 P04150 1/20 0.40
FYN P06241 1/20 0.40
ADRA2A P08913 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2342978 1.00 LMNA (0.59) LMNAKMT2APOLBALDH1A1CYP3A4
SCHEMBL31540813 0.92 LMNA (0.56) LMNAKMT2APOLBALDH1A1CYP3A4
SCHEMBL2336949 0.92 LMNA (0.67) LMNAKMT2APOLBALDH1A1CYP3A4
SCHEMBL17784084 0.92 LMNA (0.67) LMNAKMT2APOLBALDH1A1CYP3A4
SCHEMBL16883909 0.91 LMNA (0.54) LMNAKMT2APOLBALDH1A1CYP3A4
SCHEMBL3336077 0.91 LMNA (0.54) LMNAKMT2APOLBALDH1A1CYP3A4
SCHEMBL3336078 0.91 LMNA (0.54) LMNAKMT2APOLBALDH1A1CYP3A4
SCHEMBL31540816 0.91 LMNA (0.55) LMNAKMT2APOLBALDH1A1CYP3A4
SCHEMBL24771437 0.87 LMNA (0.69) LMNAKMT2APOLBALDH1A1CYP3A4
SCHEMBL16259533 0.87 LMNA (0.69) LMNAKMT2APOLBALDH1A1CYP3A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20160151400-A1 HYBRID SCFA-HYDROXYL-DERIVATIZED MONOSACCHARIDES, METHODS OF SYNTHESIS, AND METHODS OF TREATING DISORDERS UNIV JOHNS HOPKINS (US) 2016-06-02 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160151400-A1 HYBRID SCFA-HYDROXYL-DERIVATIZED MONOSACCHARIDES, METHODS OF SYNTHESIS, AND METHODS OF TREATING DISORDERS HCAR2, HSD17B14, FASN LMNA 1218/4885KMT2A 1073/4885POLB 4304/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.